Active pharmaceutical ingredients (APIs) are entrenched in the foundations of Lupin and are a backbone to the organization.

Historically, along with being one of the most vertically integrated pharmaceutical companies Lupin has also consciously focused on building scale and efficiencies-making it an undisputed leader in its chosen product segments.

Lupin has remained a global leader in therapeutic segments such as Cephalosporins, Cardiovascular and the Anti-TB space for over 15 years.

For the FY 2015 revenue from our API business was Rs.11,941 million as compared to Rs.9,498 million in FY 2013, growing at a CAGR of 12 % despite price pressures.

The Company has re-focused its API group into making further inroads into markets such as US, Europe, Japan and exploring new opportunities in emerging markets like China, Brazil, Mexico, Korea and Russia.

As part of its new growth plan Lupin’s API business targets on developing 4-6 new APIs per quarter with renewed focus & investment on API R&D

The newer APIs will be spread across therapeutic areas including, but not limited to – Anti-Viral, Anti-Diabetics, Anti-Neoplastics etc.

The Company has embarked on some key initiatives that are going to drive the future growth of the business including adoption of greener chemistry technologies with the dual purpose of improving efficiencies and protecting the environment & Augmenting current established capacities with investment in Greenfield projects.

Additionally Lupin has also has retained its leading position as one of the few coveted suppliers of Anti-TB products to the World Health Organization’s (WHO’s) Global Drug Facility. Lupin has the unique distinction of being the only company to have both its APIs and formulations for TB products prequalified by the WHO globally.

It has consolidated its institutional business to include Anti retroviral, Oral contraceptives.